ArticleJournal of pharmacokinetics and pharmacodynamics2001
In vivo-in vitro correlation (IVIVC) modeling incorporating a convolution step.
Article in Journal of pharmacokinetics and pharmacodynamics, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A novel beads-based dissolution method for the in vitro evaluation of extended release HPMC matrix tablets and the correlation with the in vivo data.The AAPS journal · 2013Trial
- Population in vitro-in vivo correlation model for pramipexole slow-release oral formulations.Pharmaceutical research · 2010Trial
- Mechanism-based classification of in vitro-in vivo correlation failures and model-informed strategies for drug product development.Archives of pharmacal research · 2026Review
- Unveiling the Future: Opportunities in Long-Acting Injectable Drug Development for Veterinary Care.Pharmaceutics · 2025Review
- Engineering Quick- and Long-acting Naloxone Delivery Systems for Treating Opioid Overdose.Pharmaceutical research · 2021Article
- Preparation and in vivo/in vitro characterization of Ticagrelor PLGA sustained-release microspheres for injection.Designed monomers and polymers · 2021Article
- Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips.Nature biomedical engineering · 2020Article
- A General Framework for Assessing In vitro/In vivo Correlation as a Tool for Maximizing the Benefit-Risk Ratio of a Treatment Using a Convolution-Based Modeling Approach.CPT: pharmacometrics & systems pharmacology · 2019Article
- Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.Pharmaceutical research · 2018Article
- Evaluating In Vivo-In Vitro Correlation Using a Bayesian Approach.The AAPS journal · 2016Article
- In vitro- in vivo correlation's dissolution limits setting.Pharmaceutical research · 2014Article
- In vitro-in vivo correlations: tricks and traps.The AAPS journal · 2012Article
- A time scaling approach to develop an in vitro-in vivo correlation (IVIVC) model using a convolution-based technique.Journal of pharmacokinetics and pharmacodynamics · 2011Article
- A population approach to in vitro-in vivo correlation modelling for compounds with nonlinear kinetics.Journal of pharmacokinetics and pharmacodynamics · 2011Article
- A nonlinear mixed effects IVIVC model for multi-release drug delivery systems.Journal of pharmacokinetics and pharmacodynamics · 2008Article
- Blood-brain barrier penetration of zolmitriptan--modelling of positron emission tomography data.Journal of pharmacokinetics and pharmacodynamics · 2006Article
- Analyzing multi-response data using forcing functions.Journal of pharmacokinetics and pharmacodynamics · 2005Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of in vivo-in vitro correlation (IVIVC) modeling is described. These models are usually fitted to deconvoluted data rather than the raw plasma drug concentration/time data. Such a two-stage analysis is undesirable because the deconvolution step is unstable and because the fitted model predicts the fraction of a dosage unit dissolved/absorbed in vivo which generally is not the primary focus of our attention. Interest usually centers on the plasma drug concentration or some function of it (e.g., AUC, Cmax). Incorporation of a convolution step into the model overcomes these difficulties. Odds, hazards, and reversed hazards models which include a convolution step are described. The identity model (which states that average in vivo and in vitro dissolution/time curves are coincident or directly superimposable) is a special case of these models. The odds model and the identity model were fitted to data sets for two different products using nonlinear mixed effects model fitting software. Results show that the odds model describes both data sets reasonably well and is a significantly better fit than the identity model in each case.
Indexed as
Identifiers
11468941What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.